Infrastructure for healthcare data has shown initial results, yet application remains weak.

According to the National Health Information Survey, less than 20% of tertiary hospitals effectively utilize medical data.

The “Data Elements ×” Three-Year Action Plan encourages circulation and transforms data from liability to asset.

Drawing from financial data practices, privacy computing and tradable “data components” are introduced to solve ownership and security barriers.

Eventually secure, efficient, and sustainable circulation of medical data will maximize asset returns.

Centralized procurement and stricter regulations have squeezed profitability.

The number of pharmaceutical companies increased but loss ratio rose since 2021.

Large pharma pursues transformation via proprietary pipelines, M&A, and global expansion.

Mid-sized and small firms focus on niche innovation and agile BD models.

As industry reshuffling concludes, growth will be driven by novel drug pipelines and overseas footprint.

Traditional Chinese Medicine showed potential during COVID-19, yet challenges remain: inconsistent diagnosis, low efficiency in production, and lack of modern explanations.

To revitalize TCM, the industry is adopting modern scientific language and cross-disciplinary methods.

New diagnostic devices, real-time dynamic monitoring, and evidence-based research will standardize prescriptions.

Integration with wellness and health tourism will deliver better social and economic benefits.

Digital technologies break time and geographical barriers, enabling high-quality resources to reach primary levels.

Regional health data networks, health-all-in-one devices, e-records, and tele-consultation are deployed.

Early movers accumulate data advantages and build primary healthcare ecosystems.

Integrated internet-based medical services become the practical solution for “strengthening the grassroots”.

Smart hospitals are core to high-quality healthcare, advancing in smart services, smart medicine, and smart management.

AI-assisted decisions, IoT-based patient journey records, and digital pre-consultation enhance efficiency.

Rating systems and integration of clinical decision support systems drive service reconfiguration.

Non-surgical aesthetic medicine grows rapidly, focusing on skin management, injectables, and energy-based devices.

Market competition shifts from price wars to brand reputation, physician credentials, and digital marketing.

Younger demographics and personalized needs drive innovation in biomaterials and collagen products.

Regulatory compliance ensures long-term healthy development.

Standardization of classic formulas and national quality standards for TCM granules are underway.

Digital traceability for herbal materials, intelligent manufacturing, and global registration accelerate.

Collaborative platforms (industry-university-research) promote secondary development of blockbuster TCM products.

Younger hair-loss population drives integrated hair health management systems.

Medical-grade treatments, low-level laser therapy, and robotic hair transplant tech are maturing.

Brands build closed loops of “diagnosis + treatment + maintenance” blending online and offline.

Generative AI empowers medical research, CDSS, patient interaction, and automated medical documentation.

LLMs trained on massive medical knowledge boost primary care diagnostic capacities and hospital administration.

Data privacy, compliance, and model interpretability remain breakthrough priorities.

Innovative drug licensing-out and medical device CE/FDA approvals are rising rapidly.

Emerging markets and developed regions become dual engines for overseas expansion.

Cross-border partnerships, overseas clinical trials, and global supply chain construction are accelerating.

Shift from “product export” to “brand globalization”.